Zusammenfassung
Die Liquoruntersuchung bei der Alzheimer Demenz (AD) dient traditionell zunächst zum differentialdiagnostischen Ausschluß überwiegend entzündlicher Erkrankungen, deren klinisches Bild sich in einem Demenzsyndrom manifestieren können. Alle chronisch verlaufenden Enzephalitiden können beispielsweise das Bild einer Demenz hervorrufen. Infektionskrankheiten mit Spirochäten (Neurolues und Lyme-Borreliose) und humanen Immundefizienzviren (HIV) sind weitere Beispiele für mögliche Einsatzgebiete der Liquoranalyse (Tabelle 9.1). Einen Sonderfall stellt u.a. der Normaldruckhydrozephalus dar, bei dem durch eine therapeutische Punktion bzw. Liquordrainage oft eine Verbesserung des klinischen Bildes innerhalb von Minuten bis Stunden erreicht werden kann.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L (1997) Cerebrospinal fluid levels of a-secretase-cleaved soluble amyloid precursor protein mirror Cognition in a Swedish family with Alzheimer’s disease. Arch Neurol 54: 641–644
Andreasen N, Vanmechelen E, Van de Voorde A et al. (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a Community based follow up study. J Neurol Neurosurg Psychiatry 64: 298–305
Arai H, Morikawa Y, Higuchi M et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236: 262–264
Arai H, Terajima M, Miura M, et al. (1995) Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38: 649–652.
Blennow K, Cowburn R, Wahlund LO, Winblad B (1998a) Der klinische Nutzen von Liquor-Markern bei der sporadischen Alzheimer-Krankheit. Alzheimer Insights 3: 4–7
Blennow K, Davidsson P, Wallin A, Ekman R (1995b) Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer’s disease?Dementia 6: 306–311
Blennow K, Vanmechelen E (1998b) Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing. J Neural Transm Suppl. 53: 223–235
Blennow K, Wallin A, Agren H, Sprenger C, Siegfried J, Vanmechelen E (1995a) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer’s disease?Mol Chem Neuropathol 26: 231–245
Buch K, Riemenschneider M, Bartenstein P, Willoch F, Müller U, Schmolke M, Guder WG, Kurz A(1998) Tau-Protein: Ein potentieller biologischer Indikator zur Früherkennung der Alzheimer-Krankheit. Nervenarzt 69: 379–385
Consensus Report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease” (1998) Neurobiol Aging 19: 109-116
Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer’s disease?Mol Chem Neuropathol 27: 195–210
Galasko D, Chang L, Motter R et al. (1998) High cerebrospinal fluid tau and low Amyloidß42 levels in the clinical diagnosis of Alzheimer’s disease and relation to ApolipoproteinE genotype. Arch Neurol 55: 937–945
Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 48: 632–635
Hampel H, Kötter U (1997) Liquordiagnostik. In: Weis S, Weber G (Hrsg) Handbuch Morbus Alzheimer. Beltz Psychologie Verlags Union, Weinheim, pp 689–751
Hampel H, Müller N(1995) Inflammatory and Immunological Mechanisms in Alzheimer’s Disease. Drug News and Perspectives 8 (10): 599–608
Hampel H, Schoen D, Schwarz MJ et al. (1997a) Interleukin-6 is not altered in cerebrospinal fluid of firstdegree relatives and patients with Alzheimer’s disease. Neurosci Lett 228: 143–146
Hampel H, Sunderland T, Padberg F, Kötter HU, Schneider C, Dukoff R, Levy J, Möller HJ(1998) Decreased soluble interleukin-6 receptor in CSF of patients with Alzheimer’s disease. Brain Res 780: 356–359
Hampel H, Teipel SJ, Padberg F et al. (in press) Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res, in press
Hock C, Golombowski S, Naser W, Müller-Spahn F(1995) Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer’s disease-correlation with degree of cognitive impairment. Ann Neurol 37: 414–415
Jensen M, Basun H, Lannfelt L (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci Lett 186: 189–191
Johnson GVW, Seubert P, Cox TM, Motter R, Brown JP, Galasko D (1997) The x protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem 68: 430–433
Kanai M, Matsubara E, Isoe K et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aßl-40, and Aßl-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44: 17–26
Kovanen J, Sulkava R (1986) Duration of postural headache after lumbar puncture: effect of needle size. Headache 26: 224–226
Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Müller U, Guder W(1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer’s disease. Alzheimer Dis Assoc Disord 12: 372–377
Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL (1995) Decreased a-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat Med 1: 829–832
Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, Kaplan EF, D‘Agostino RB(1995) The “preclinical phase”of probable Alzheimer’s disease. Arch Neurol 52: 485–490
Mori H, Hosoda K, Matsubara E et al. (1995) Tau in cerebrospinal fluids: establishment of the Sandwich ELISA with an antibody specific to the repeat sequence in tau. Neurosci Lett 186: 181–183
Motter R, Vigo-Pelfrey C, Kholodenko D et al. (1995) Reduction of ß-Amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38: 643–648
Müller B, Adelt K, Reichmann H, Toyka K (1994) Atraumatic needle reduces the incidence of post-lumbar puncture Syndrome. J Neurol 241: 376–380
Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CL, Fu PC, Whaley JM, Wolfert RL (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. Ann Clin Lab Sei 25: 207–217
Nitsch RM, Rebeck GW, Deng M et al. (1995) Cerebrospinal fluid levels of amyloid ß-protein in Alzheimer’s disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 37: 512–518
Ohm TG, Müller H, Braak H, Bohl J(1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 164: 209–217
Pitschke M, Prior R, Haupt M, Riesner D (1998) Detection of Single amyloid ß-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopy. Nat Med 4: 832–834
Prior R, Monning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, Masters CL, Beyreuther K (1991) Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 124: 69–73
Reiber H (1980) The discrimination between different blood-CSF-barrier dysfunetions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerbrospinal fluid. J Neurol 224: 89–99.
Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1996) Cerebrospinal protein tau is elevated in early Alzheimer’s disease. Neurosci Lett 212: 209–211
Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1997) Diagnosis of Alzheimer’s disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet 350: 784
Rösler N, Wichart I, Jellinger KA (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 60: 237–238
Schlaf G, Salje C, Wetter A, Stuertz K, Felgenhauer K, Mader M (1998) Determinatio of synapsin I and synaptophysin in body fluids by two-site enzyme-linked immunosorbent assays. J Immunol Methods 213: 191–199
Shoji M, Matsubara E, Kanai M et al. (1998) Combination assay of CSF tau, Aßl-40 and Aßl-42 (43) as a biochemical marker of Alzheimer’s disease. J Neurol Sei 158: 134–140
Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4:433–442
Strupp M, Brandt T (1997) Should one reinsert the stylet during lumbar puneture?N Engl J Med 336:1190
Strupp M, Brandt T, Müller A(1998) Incidence of post-lumbar puneture Syndrome reduced by reinserting the stylet: A randomized prospective study of 600 patients. J Neurol 245: 589–592
Tamaoka A, Sawamura N, Fukushima T et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Sei 148: 41–45
Tapiola T, Lehtovirta M, Pirttilä T, Alafuzoff I, Riekkinen P, Soininen H(1998) Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer’s disease. Lancet 352: 287
Tato RA, Frank A, Hernanz A (1995) Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 59: 280–283
Urakami K, Takahashi K, Saito H et al. (1992) Amyloid beta protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. Acta Neurol Scand 85: 343–346
Van Nostrand WE, Wagner SL, Shankle WR et al. (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sei USA 89: 2551–2555
Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin JJ, Cras P (1993) Detection of x proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzymelinked immunosorbent assay. J Neurochem 61: 1828–1834
Vigo-Pelfrey C, Seubert P, Barbour R et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45: 788–793
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hampel, H., Bürger, K., Padberg, F., Bahro, M. (1999). Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. In: Förstl, H., Bickel, H., Kurz, A. (eds) Alzheimer Demenz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60228-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-60228-3_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64313-2
Online ISBN: 978-3-642-60228-3
eBook Packages: Springer Book Archive